Overall verdict
Buy
6.9/10
1-year performance
+43.10%
Score breakdown
Up 43.1% over 1 year, 96% of the 52-week range.
Strongest: Profitability 10.0/10. Weakest: Financial strength 2.8/10.
21 analysts, target +0.0% vs the price.
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services ;
real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes ; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order ;
and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services.
The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.
Sector
Health Care
Industry
Life Sciences Tools and Services
Primary listing
Nyse
United States
CEO
Ari Bousbib
Founded
—
Employees
93 000
Revenue / employee
175 312 USD
Next earnings
October 28, 2026 (estimated)
Institutional holders
- BlackRock, Inc.9.00%
- HARRIS ASSOCIATES L P7.54%
- VANGUARD CAPITAL MANAGEMENT LLC6.75%
- STATE STREET CORP4.64%
- VANGUARD PORTFOLIO MANAGEMENT LLC4.64%
- JPMORGAN CHASE & CO3.80%
- Artisan Partners Limited Partnership2.93%
- Boston Partners2.76%
- GEODE CAPITAL MANAGEMENT, LLC2.76%
- Other institutions51.76%
- Rest of the register3.42%
1088 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
277.40 USD
52-week low
154.50 USD
1-year performance
43.10%
Rising
Year-to-date performance
18.83%
Rising
Drawdown
-1.68%
Near its high
Position in the 52-week range
96% of range
Against the world ETF
Over 13 years, from May 2013 to August 2026, the share did not do better than the world ETF once risk is accounted for. It earned more, but shaking 2.4 times harder: for the risk taken, the ETF paid better.
10,000 € placed at the end of May 2013 are worth today
| IQVIA Holdings | 66 413 € |
| World ETF | 47 218 € |
| S&P 500 | 65 880 € |
| Risk-free placement | 10 950 € |
The risk
- Shaking:the share moves 2.4 times as much as the world ETF.
- Worst fall:-52 % between December 2021 and May 2025. 10,000 € placed at the top fell to 4 834 €. The world ETF, at worst: -34 %. The share has not returned to its high yet.
IQVIA Holdings earned more than the world ETF since 2013
Value of 10,000 euros placed at the end of May 2013, dividends reinvested, in euros
- IQVIA Holdings: 66 413 €
- World ETF: 47 218 €
- S&P 500: 65 880 €
- Risk-free placement: 10 950 €
Based on past performance. This is not a recommendation.
Range: 247.00 USD - 255.90 USD (3 methods agree)
The price implies growth of 5.12% per year; the company grows at 25.00%.
Quality and profitability
10.0/10Gross margin 26.0%, net margin 8.1%, ROIC 6.8%, ROE 23.0%.
Net margin
8.09%
Exceptional
Sector 5.47%|S&P 12.97%
Gross margin
26.02%
Low
Return on equity (ROE)
23.01%
Exceptional
Sector 3.01%|S&P 16.52%
Return on invested capital (ROIC)
6.83%
Exceptional
Free cash flow margin (FCF)
12.86%
Exceptional
Profit-to-cash conversion (FCF conversion)
1.59x
Exceptional
Margin stability
3.8 pts
Steady
Revenue to net income
Growth
3.5/10Revenue up 8.8% over 1 year, 7.5% a year over 5, EPS 40.5% a year over 5.
Revenue (trailing 12 months)
17.0Md USD
Revenue growth (1y)
8.84%
Solid
Revenue growth (3y)
13.07%
Moderate
EPS growth (1y)
-0.36%
Declining
EPS CAGR (5y)
40.52%
Exceptional
EPS revisions (3 months)
1.19%
Revised up
Valuation
8.8/10P/E 33.8x, forward P/E 35.1x, EV/EBITDA 15.6x, PEG 0.83. The multiple sits in the 62th percentile of its own 5-year history.
P/E (TTM)
33.8x
Fair
Sector 51.0x|S&P 23.0x
Forward P/E
35.1x
Fair
EV / EBITDA
15.6x
Cheap
Sector 28.4x|S&P 14.5x
PEG
0.83
Growth unpriced
Sector 0.12|S&P 0.86
Fair value (reverse DCF)
249.69 USD
Fairly priced
P/E vs its own 5-year history
among the 38% highest valuations
Pricier than usual
Market cap
44.1Md USD
Financial strength
2.8/10Cash covers 12.8% of the debt, net debt/EBITDA 4.1x.
Net debt / EBITDA
4.1x
Stretched
Gearing (net debt / equity)
224.74%
Stretched
Cash
2.1Md USD
Cash / market cap
4.72%
Tight
Cash / total debt
12.81%
Stretched
Interest coverage
2.9x
Tight
Net debt
14.2Md USD
Equity
6.3Md USD
Closed daily candles, 2 years
Last close on September 24, 2026: 275.02 USD
- MM20265.25
- MM50246.40
- MM200204.52
- RSI 1467.1
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+2.25%
200-day average slope, 3 months
+4.80%
50-day average slope, 1 month
+14.02%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
1.49 % per day
Volatility change
-42.03%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 7.76 (11) | 12.97 (21) | 17 414 (18) | 4 035 (14) | 1 276 (11) |
| 2027 | 9.73 (11) | 14.46 (21) | 18 469 (18) | 4 306 (14) | 1 580 (11) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 16, 2026.
Same sub-industry: 103 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 603259 | 8.0 | 8.0 | 75.1Md USD | 22.2x | 40.2 % | 47.7 % | 29.5 % | -1.7x | 2.6 % | 56.1 % | ||
| 2 | A207940 | 7.5 | 7.9 | 46.0Md USD | 31.8x | 39.9 % | 30.2 % | 16.6 % | -0.2x | 2.3 % | -13.0 % | ||
| 3 | IQV | 6.9 | 6.9 | 44.1Md USD | 33.8x | 8.1 % | 8.8 % | 6.8 % | 4.1x | 5.0 % | 43.1 % | ||
| 4 | A | 6.7 | 7.2 | 46.6Md USD | 32.5x | 19.5 % | 8.1 % | 13.9 % | 0.9x | 2.7 % | 38.1 % | ||
| 5 | DHR | 6.4 | 6.5 | 156Md USD | 39.3x | 15.9 % | 5.5 % | 5.4 % | 2.0x | 3.5 % | 18.6 % | ||
| 6 | LONN | 6.3 | 6.1 | 46.4Md USD | Not meaningful (loss) | 16.7 % | 19.2 % | 8.7 % | 1.9x | 0.6 % | 6.1 % | ||
| 7 | TMO | 6.0 | 5.9 | 246Md USD | 35.8x | 15.0 % | 10.5 % | 7.9 % | 2.8x | 3.0 % | 45.0 % | ||
| 8 | ILMN | 4.9 | 5.1 | 38.6Md USD | 47.6x | 18.4 % | 9.8 % | 18.2 % | 0.8x | 2.4 % | 175.3 % | ||
| 9 | WAT | 4.8 | 3.8 | 41.3Md USD | 105.0x | 3.6 % | 113.3 % | 1.4 % | 0.8x | 0.9 % | 44.7 % |
